GlassScriptPhysician profile
Hanna Jay Stragand
NPI 1770185159
$1,886.94
in general payments reported to CMS, 2019-2025
24 companies · $572 in 2025
The $572 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $203 · 2023: $364 · 2024: $748 · 2025: $572.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,624 · Gift: $59.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,624.19 |
| Gift | $59.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mannkind Corporation | $288.75 | 2023-2025 | Afrezza, V-Go |
| Novo Nordisk INC | $250.98 | 2022-2025 | Ozempic |
| Lilly USA, LLC | $227.12 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Dexcom, INC. | $149.96 | 2023-2024 | Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $122.33 | 2023-2025 | Jardiance |
| Fresenius USA Marketing, INC. | $85.13 | 2024-2025 | Velphoro, Velphoro |
| Otsuka America Pharmaceutical, INC. | $82.08 | 2024-2025 | Jynarque |
| Bayer Healthcare Pharmaceuticals INC. | $79.46 | 2024-2025 | |
| Alexion Pharmaceuticals, INC. | $75.62 | 2024-2025 | Strensiq |
| Medtronic, INC. | $71.15 | 2022-2025 | Minimed 780g |
| Amgen INC. | $65.79 | 2024-2025 | Tavneos |
| Ardelyx, INC. | $52.85 | 2024-2025 | Ibsrela |
| Ascendis Pharma Endocrinology INC | $49.99 | 2024-2025 | Yorvipath |
| Insulet Corporation | $49.61 | 2024-2025 | Omnipod |
| Sanofi-Aventis U.S. LLC | $41.72 | 2024-2025 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Travere Therapeutics, INC. | $29.99 | 2025 | |
| Beta Bionics, INC. | $25.08 | 2024 | Ilet Bionic Pancreas |
| Calliditas Therapeutics US INC. | $24.28 | 2025 | Tarpeyo |
| Recordati_rare_diseases_inc. | $22.79 | 2025 | Signifor Lar |
| Amneal Pharmaceuticals LLC | $22.66 | 2024 | Unithroid |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $18.80 | 2025 | |
| Pfizer INC. | $18.78 | 2024 | |
| Novartis Pharmaceuticals Corporation | $17.56 | 2024 | |
| Tandem Diabetes Care, INC. | $14.46 | 2024 | T:Slim X2 Insulin Pump With Control-Iq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hanna Stragand listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.